详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. [2]Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China. [3]School of Food and Bioengineering, Chengdu University, Chengdu, Sichuan, China.

出处：

DOI：

ISSN：

关键词： arachidonic acid inflammation oxidative stress acute kidney injury chronic kidney disease renal cell carcinoma

摘要：

Arachidonic acid (AA) is a main component of cell membrane lipids. AA is mainly metabolized by three enzymes: cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP450). Esterified AA is hydrolysed by phospholipase A2 into a free form that is further metabolized by COX, LOX and CYP450 to a wide range of bioactive mediators, including prostaglandins, lipoxins, thromboxanes, leukotrienes, hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids. Increased mitochondrial oxidative stress is considered to be a central mechanism in the pathophysiology of the kidney. Along with increased oxidative stress, apoptosis, inflammation and tissue fibrosis drive the progressive loss of kidney function, affecting the glomerular filtration barrier and the tubulointerstitium. Recent studies have shown that AA and its active derivative eicosanoids play important roles in the regulation of physiological kidney function and the pathogenesis of kidney disease. These factors are potentially novel biomarkers, especially in the context of their involvement in inflammatory processes and oxidative stress. In this review, we introduce the three main metabolic pathways of AA and discuss the molecular mechanisms by which these pathways affect the progression of acute kidney injury (AKI), diabetic nephropathy (DN) and renal cell carcinoma (RCC). This review may provide new therapeutic targets for the identification of AKI to CKD continuum.Copyright © 2024 Li, Suo, Wang, Zou, Nie, Zhao and Miao.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 2 区药学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区药学

第一作者：

第一作者机构： [1]School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. [2]Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Dihydroartemisinin attenuates lipopolysaccharide-induced acute kidney injury by inhibiting inflammation and oxidative stress. [2]Association between Prognostic Nutritional Index and Contrast-Associated Acute Kidney Injury in Patients Complicated with Chronic Kidney Disease and Coronary Artery Disease [3]Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREAtinine Measurement project. [4]The effect of monotropein on alleviating cisplatin-induced acute kidney injury by inhibiting oxidative damage, inflammation and apoptosis. [5]SHORT AND LONG-TERM OUTCOMES AFTER INCIDENT PNEUMONIA IN ADULTS WITH CHRONIC KIDNEY DISEASE: A TIME-DEPENDENT ANALYSIS FROM THE SCREAM PROJECT [6]Artesunate-Nanoliposome-TPP, a Novel Drug Delivery System That Targets the Mitochondria, Attenuates Cisplatin-Induced Acute Kidney Injury by Suppressing Oxidative Stress and Inflammatory Effects [7]A Comparison Between Two Different Definitions of Contrast-Associated Acute Kidney Injury for Long-Term Mortality in Patients with Chronic Kidney Disease Undergoing Coronary Angiography [8]The Long Noncoding RNA-H19 Mediates the Progression of Fibrosis from Acute Kidney Injury to Chronic Kidney Disease by Regulating the miR-196a/Wnt/β-Catenin Signaling. [9]Huangqi-Danshen decoction protects against cisplatin-induced acute kidney injury in mice [10]Curcumin ameliorates CKD-induced mitochondrial dysfunction and oxidative stress through inhibiting GSK-3β activity.